CLONING OF HUMAN TUMOR CELLS IN TISSUE CULTURE SYSTEMS

已经证明了毛细血管瘤的可行性 第一阶段的克隆形成细胞试验，第二阶段的初步努力 合同将是这个系统的优化和评估， 本试验应用于研究的生长动力学， 在毛细管中生长的菌落， 该系统的放射性同位素终点，以及 选定的抗癌药物的稳定性-根据分析 条件-在这个系统中。 这已经完成，在 与顾问合作，该系统将用于 患者反应的前瞻性临床相关性 化疗及其肿瘤的体外敏感性， 通过该试验确定。 入组本研究的患者将 由顾问进行为期两年的研究， 为了评价本试验的可预测性，选择 抗肿瘤药物和患者反应。 最后 应用该测定作为筛选潜在的 将研究新的抗肿瘤剂。

Having demonstrated the feasibility of the capillary tumor clonogenic cell assay in Phase I, the initial effort of the Phase II contract will be the optimization and evaluation of this system, the application of this assay to the study of the growth kinetics of colonies grown in the capillary tubes, the feasibility of a radioisotope endpoint for this system, and the determination of the stability of selected anti-cancer drugs - under the assay conditions - in this system. This having been accomplished, in collaboration with consultants, this system will be used in a prospective clinical correlation of patients' response to chemotherapy and the in vitro sensitivity of their tumors as determine by this assay. Patients entered into this study will be followed for a period of two years - by the consultants - in order to evaluate the predictability of this assay with the selection of the anti-neoplastic agent and patient response. Finally, the application of this assay as a tool for the screening of potential new anti-neoplastic agents will be studied.